FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)

DRUG6 trials

Conditions

Hepatic Arterial Infusion ChemotherapyIntrahepatic Cholangiocarcinoma (Icc)Intrahepatic Cholangiocellular CarcinomaLocally Advanced Colorectal CancerLocally Advanced Rectal CarcinomaMetastatic Colorectal Cancer

Phase 1

A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

CompletedNCT00494221

AstraZenecaMetastatic Colorectal Cancer

Start: 2007-06-30End: 2012-08-31Updated: 2014-03-27

Phase 2

Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

RecruitingNCT06860477

Fudan UniversityIntrahepatic Cholangiocellular Carcinoma

Start: 2025-03-18End: 2028-03-15Target: 92Updated: 2025-04-06

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Not yet recruitingNCT07353827

Sun Yat-sen UniversityHepatic Arterial Infusion Chemotherapy, Intrahepatic Cholangiocarcinoma (Icc)

Start: 2026-02-01End: 2028-12-31Target: 36Updated: 2026-01-20

Phase 3

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

CompletedNCT00399035

AstraZenecaMetastatic Colorectal Cancer

Start: 2006-11-30End: 2016-08-31Updated: 2016-12-28

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Not yet recruitingNCT06783491

Maimónides Biomedical Research Institute of CórdobaLocally Advanced Colorectal Cancer

Start: 2025-12-31End: 2030-12-31Target: 1083Updated: 2025-11-24

Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

Not yet recruitingNCT07472868

J. W. A. BurgerLocally Advanced Rectal Carcinoma

Start: 2026-03-03End: 2034-03-02Target: 394Updated: 2026-03-16

Related Papers

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.